An Act amending the act of April 17, 2016 (P.L.84, No.16), known as the Medical Marijuana Act, in preliminary provisions, further providing for definitions.

PRINTER'S NO. 526
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE BILL
No. 533
Session of
2025
INTRODUCED BY McNEILL, WAXMAN, MADDEN, GIRAL AND HOHENSTEIN,
FEBRUARY 10, 2025
REFERRED TO COMMITTEE ON HEALTH, FEBRUARY 10, 2025
AN ACT
Amending the act of April 17, 2016 (P.L.84, No.16), entitled "An
act establishing a medical marijuana program; providing for
patient and caregiver certification and for medical marijuana
organization registration; imposing duties on the Department
of Health; providing for a tax on medical marijuana
organization gross receipts; establishing the Medical
Marijuana Program Fund; establishing the Medical Marijuana
Advisory Board; establishing a medical marijuana research
program; imposing duties on the Department of Corrections,
the Department of Education and the Department of Human
Services; and providing for academic clinical research
centers and for penalties and enforcement," in preliminary
provisions, further providing for definitions.
The General Assembly of the Commonwealth of Pennsylvania
hereby enacts as follows:
Section 1. The definition of "serious medical condition" in
section 103 of the act of April 17, 2016 (P.L.84, No.16), known
as the Medical Marijuana Act, is amended to read:
Section 103. Definitions.
The following words and phrases when used in this act shall
have the meanings given to them in this section unless the
context clearly indicates otherwise:
* * *
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
"Serious medical condition." Any of the following:
(1) Cancer, including remission therapy.
(2) Positive status for human immunodeficiency virus or
acquired immune deficiency syndrome.
(3) Amyotrophic lateral sclerosis.
(4) Parkinson's disease.
(5) Multiple sclerosis.
(6) Damage to the nervous tissue of the central nervous
system (brain-spinal cord) with objective neurological
indication of intractable spasticity and other associated
neuropathies.
(7) Epilepsy.
(8) Inflammatory bowel disease.
(9) Neuropathies.
(10) Huntington's disease.
(11) Crohn's disease.
(12) Post-traumatic stress disorder.
(13) Intractable seizures.
(14) Glaucoma.
(15) Sickle cell anemia.
(16) Severe chronic or intractable pain of neuropathic
origin or severe chronic or intractable pain.
(17) Autism.
(17.1) A condition deemed a serious medical condition by
a practitioner.
(18) Other conditions that are recommended by the
advisory board and approved by the secretary under section
1202.
* * *
Section 2. This act shall take effect in 60 days.
20250HB0533PN0526 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30